Director's Dealing • Mar 2, 2023
Director's Dealing
Open in ViewerOpens in native device viewer
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
Check this box if no longer subject to
Instruction 1(b).
Section 16. Form 4 or
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person Inbar |
Galia | 2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director _ 10% Owner |
|||||
|---|---|---|---|---|---|---|---|---|
| (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
3. Date of Earliest Transaction (Month/Day/Year) 02/28/2023 |
Officer (give title below)____ Other (specify below) X See "Remarks" |
||||||
| (Street) Tel Aviv L3 6944020 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month/Day/Year) |
2A. Deemed Execution Date, if any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||
| (1) Ordinary Shares |
02/28/2023 | M | 4,828 | A | (2) | 20,194 | D |
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month/Day/Year) |
3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number 6. Date Exercisable and of Expiration Date Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable |
Expiration Date |
Title | Amount or Number of Shares |
||||||||
| Restricted Share Units |
(2) | 02/28/2023 | M | 4,828 | (3) | (3) | Ordinary Shares (1) |
4,828 | \$ 0 |
4,829 | D |
(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(3) Restricted share units were granted on February 28, 2020 with 4,828 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 4,829 vesting on February 28, 2024.
EVP, Chief Human Resources Officer and Corporate Affairs
/s/ Dov Bergwerk as attorney-in-fact for Galia Inbar 03/02/2023
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.